Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared on LinkedIn:
“Honored to receive the ‘Leadership in Cancer Drug Development 2026’ award from the WIN Symposium leadership team.
This award belongs to the patients whose courage in clinical trials moves our science and everyone who I cannot fit here for the support.
Thankful and grateful.
Tumor‑agnostic drug development continues geography and zip code agnostic.”
Other posts about WIN Symposium 2026 on OncoDaily.
